Her2 Negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Her2 Negative Breast Cancer Overview

Breast cancer is the most common cancer among women other than skin cancer. Increasing age is the most common risk factor for developing breast cancer, with 66% of breast cancer patients being diagnosed after the age of 55. Cancer is uncontrolled cell growth. Breast cancer means these cells started in the breast, though they may spread to nearby tissue and organs and eventually to anywhere in the body. HER2 stands for human epidermal growth factor receptor-2. It’s healthy in normal amounts, but too much may be a sign of a certain type of breast cancer.

“Her2 Negative Breast Cancer Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Her2 Negative Breast Cancer Market. 

The Her2 Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Her2 Negative Breast Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Her2 Negative Breast Cancer treatment therapies with a considerable amount of success over the years. Her2 Negative Breast Cancer Key players such as – Sparc Life, InventisBio, Olema Pharmaceuticals, Beta Pharma, Tyme Technologies, CytomX Therapeutics, H3 Biomedicine, Eisai, Roche, Genentech, AstraZeneca, and others, are developing therapies for the Her2 Negative Breast Cancer treatment 

• Her2 Negative Breast Cancer Emerging therapies such as – SCO-120, D-0502, OP-1250, BPI-1178, SM-88, CX-2009, H3B-6545, GDC-9545, Ipatasertib, AZD9833, and others are expected to have a significant impact on the Her2 Negative Breast Cancer market in the coming years.   
• In December 2020, CytomX Therapeutics initiated a Phase II, open-label study to evaluate the safety and antitumor activity of Praluzatamab Ravtansine (CX-2009) in advanced HR-Positive/HER2-Negative Breast Cancer and ofPraluzatamab Ravtansine as monotherapy and in combination With Pacmilimab (CX-072) in advanced Triple-Negative Breast Cancer (CTMX-2009-002)
• In January 2021, AstraZeneca initiated SERENA-4: A randomised, multicentre, double-blind, Phase III study ofAZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the treatment of patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer who have not received any systemic treatment for Advanced Disease 

Her2 Negative Breast Cancer Pipeline Therapeutics Assessment

• Her2 Negative Breast Cancer Assessment by Product Type
• Her2 Negative Breast Cancer By Stage and Product Type
• Her2 Negative Breast Cancer Assessment by Route of Administration
• Her2 Negative Breast Cancer By Stage and Route of Administration
• Her2 Negative Breast Cancer Assessment by Molecule Type
• Her2 Negative Breast Cancer by Stage and Molecule Type 

DelveInsight’s Her2 Negative Breast Cancer Report covers around 85+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Her2 Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

• SCO-120: Sparc Life
• D-0502: InventisBio
• OP-1250: Olema Pharmaceuticals
• BPI-1178: Beta Pharma
• SM-88: Tyme Technologies
• CX-2009: CytomX Therapeutics
• H3B-6545: H3 Biomedicine/Eisai
• GDC-9545: Roche
• Ipatasertib: Genentech
• AZD9833: AstraZeneca 

Her2 Negative Breast Cancer Pipeline Analysis:

The Her2 Negative Breast Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Her2 Negative Breast Cancer treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Her2 Negative Breast Cancer Treatment.
• Her2 Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Her2 Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Her2 Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Her2 Negative Breast Cancer product details are provided in the report. Download the Her2 Negative Breast Cancer pipeline report to learn more about the emerging Her2 Negative Breast Cancer therapies

Her2 Negative Breast Cancer Pipeline Market Drivers

• HER2 protein is considered a relevant biomarker for treatment
• Growing prevalence of Breast Cancer

Her2 Negative Breast Cancer Pipeline Market Barriers

• Poor understanding in the context of breast cancer subtype
• Lack of research in identification of factors involved in resistance

Get a Free Sample PDF Report to know more about Her2 Negative Breast Cancer Pipeline Assessment

Scope of Her2 Negative Breast Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Her2 Negative Breast Cancer Companies: Sparc Life, InventisBio, Olema Pharmaceuticals, Beta Pharma, Tyme Technologies, CytomX Therapeutics, H3 Biomedicine, Eisai, Roche, Genentech, AstraZeneca, and others
• Key Her2 Negative Breast Cancer Therapies: SCO-120, D-0502, OP-1250, BPI-1178, SM-88, CX-2009, H3B-6545, GDC-9545, Ipatasertib, AZD9833, and others
• Her2 Negative Breast Cancer Therapeutic Assessment: Her2 Negative Breast Cancer current marketed and Her2 Negative Breast Cancer emerging therapies
• Her2 Negative Breast Cancer Market Dynamics:  Her2 Negative Breast Cancer market drivers and Her2 Negative Breast Cancer market barriers 

Request for Sample PDF Report for Her2 Negative Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Her2 Negative Breast Cancer drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com